

# Daniel A Hamstra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/617957/publications.pdf>

Version: 2024-02-01

95  
papers

5,357  
citations

87888

38  
h-index

82547

72  
g-index

95  
all docs

95  
docs citations

95  
times ranked

6065  
citing authors

#	ARTICLE	IF	CITATIONS
1	Preparing Patients with Early Stage Prostate Cancer to Participate in Clinical Appointments Using a Shared Decision Making Training Video. <i>Medical Decision Making</i> , 2022, 42, 364-374.	2.4	5
2	Oral D-methionine protects against cisplatin-induced hearing loss in humans: phase 2 randomized clinical trial in India. <i>International Journal of Audiology</i> , 2022, 61, 621-631.	1.7	14
3	Patient Reported Outcomes for Quality of Life (QOL) By Expanded Prostate Cancer Index (EPIC) on Average 15 Years Post Treatment. <i>Clinical and Translational Radiation Oncology</i> , 2022, , .	1.7	3
4	Evaluating the correlation between early and late quality-of-life declines using the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) after definitive stereotactic body radiotherapy, intensity-modulated radiotherapy, or brachytherapy for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 214-214.	1.6	3
5	Patient-Reported Quality of Life During Prostate Cancer Radiation Therapy: Insights Into the Patient Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1129-1131.	0.8	0
6	Ethical Allocation of Proton Therapy and the Insurance Review Process. <i>Practical Radiation Oncology</i> , 2021, 11, e449-e458.	2.1	0
7	Who Benefits From a Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial. <i>Practical Radiation Oncology</i> , 2020, 10, 186-194.	2.1	13
8	Rectal Spacer Usage with Proton Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 644-648.	0.8	7
9	Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: a pooled prospective evaluation of bowel-associated quality of life. <i>BJU International</i> , 2020, 126, 367-372.	2.5	16
10	Local control matters. <i>Translational Andrology and Urology</i> , 2020, 9, 991-996.	1.4	1
11	Trimodality therapy for atypical teratoid/rhabdoid tumor is associated with improved overall survival: A surveillance, epidemiology, and end results analysis. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27969.	1.5	19
12	Hypofractionation in Prostate Cancer Using Proton Beam. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 723-726.	0.8	3
13	Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. <i>Radiotherapy and Oncology</i> , 2019, 141, 137-143.	0.6	8
14	Spinal Growth Patterns After Craniospinal Irradiation in Children With Medulloblastoma. <i>Practical Radiation Oncology</i> , 2019, 9, e22-e28.	2.1	8
15	Changes in prostate orientation due to removal of a Foley catheter. <i>Medical Physics</i> , 2018, 45, 1369-1378.	3.0	13
16	Double-blind placebo-controlled multicenter phase II trial to evaluate D-methionine in preventing/reducing oral mucositis induced by radiation and chemotherapy for head and neck cancer. <i>Head and Neck</i> , 2018, 40, 1375-1388.	2.0	21
17	Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, e180039.	7.1	238
18	Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 376-386.	0.8	7

#	ARTICLE	IF	CITATIONS
19	Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial. <i>Practical Radiation Oncology</i> , 2018, 8, e7-e15.	2.1	43
20	Erectile function after stereotactic body radiotherapy for localized prostate cancer. <i>BJU International</i> , 2018, 121, 61-68.	2.5	24
21	A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. <i>Practical Radiation Oncology</i> , 2018, 8, 40-47.	2.1	27
22	Knowledge-based treatment planning and its potential role in the transition between treatment planning systems. <i>Medical Dosimetry</i> , 2018, 43, 251-257.	0.9	8
23	Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data. <i>Urology</i> , 2018, 115, 39-44.	1.0	75
24	Quality of life is not compromised with intensification of androgen therapy in recurrent prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, 1275-1276.	10.7	1
25	Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. <i>Cancer</i> , 2017, 123, 1635-1642.	4.1	14
26	Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 976-985.	0.8	276
27	Brainstem Low-Grade Gliomas in Children—Excellent Outcomes With Multimodality Therapy. <i>Journal of Child Neurology</i> , 2017, 32, 194-203.	1.4	21
28	Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 181-188.	1.3	11
29	MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. <i>Neoplasia</i> , 2016, 18, 213-222.	5.3	51
30	Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 770-777.	0.8	11
31	Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy—A Multi-Institutional Observational Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 1046-1053.	0.8	47
32	Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase III trials. <i>Radiotherapy and Oncology</i> , 2016, 121, 193-198.	0.6	36
33	Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2016, 34, 3648-3654.	1.6	296
34	Symptom burden and information needs in prostate cancer survivors: a case for tailored long-term survivorship care. <i>BJU International</i> , 2016, 118, 372-378.	2.5	56
35	Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. <i>European Urology</i> , 2016, 69, 50-57.	1.9	30
36	Time to Nadir PSA. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 465-471.	1.3	13

#	ARTICLE	IF	CITATIONS
37	The Impact of Numeracy on Verbatim Knowledge of the Longitudinal Risk for Prostate Cancer Recurrence following Radiation Therapy. <i>Medical Decision Making</i> , 2015, 35, 27-36.	2.4	30
38	Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5. <i>Brachytherapy</i> , 2015, 14, 502-510.	0.5	23
39	Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. <i>European Urology</i> , 2015, 67, 460-467.	1.9	190
40	A Multi-Institutional Experience in Pediatric High-Grade Glioma. <i>Frontiers in Oncology</i> , 2015, 5, 28.	2.8	19
41	A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 294-302.	0.8	60
42	Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series. <i>Asian Journal of Urology</i> , 2015, 2, 53-58.	1.2	12
43	Impact of biochemical failure classification on clinical outcome: A secondary analysis of RADIATION THERAPY ONCOLOGY GROUP 9202 and 9413. <i>Cancer</i> , 2015, 121, 844-852.	4.1	3
44	Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. <i>Radiotherapy and Oncology</i> , 2015, 116, 179-184.	0.6	61
45	Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 971-977.	0.8	285
46	RE: Mortality After Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt463-djt463.	6.3	1
47	Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. <i>Cancer</i> , 2014, 120, 1076-1082.	4.1	82
48	Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy. <i>Radiation Oncology</i> , 2014, 9, 245.	2.7	2
49	Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiation. <i>Molecular and Clinical Oncology</i> , 2014, 2, 479-487.	1.0	10
50	A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy. <i>Practical Radiation Oncology</i> , 2014, 4, 422-429.	2.1	7
51	Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2014, 110, 291-297.	0.6	39
52	Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. <i>Practical Radiation Oncology</i> , 2014, 4, 99-107.	2.1	9
53	Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series.. <i>Journal of Clinical Oncology</i> , 2014, 32, 15-15.	1.6	0
54	Multi-institutional Prospective Evaluation of Bowel Quality of Life After Prostate External Beam Radiation Therapy Identifies Patient and Treatment Factors Associated With Patient-Reported Outcomes: The PROSTQA Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 546-553.	0.8	36

#	ARTICLE	IF	CITATIONS
55	Neoadjuvant Androgen Deprivation Therapy Leads to Immediate Impairment of Vitality/Hormonal and Sexual Quality of Life: Results of a Multicenter Prospective Study. <i>Urology</i> , 2013, 82, 1363-1369.	1.0	20
56	Age and Comorbid Illness Are Associated With Late Rectal Toxicity Following Dose-Escalated Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1246-1253.	0.8	43
57	The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. <i>Cancer</i> , 2013, 119, 681-690.	4.1	44
58	Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. <i>Cancer</i> , 2013, 119, 3287-3294.	4.1	51
59	Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. <i>Cancer</i> , 2013, 119, 1729-1735.	4.1	83
60	Maximum tumor diameter as a predictor for outcome following salvage radiation for prostate cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 78-78.	1.6	0
61	PSA doubling time of $\leq 6$ months as the optimal cutoff for predicting clinically relevant outcomes for men receiving salvage radiation therapy post radical prostatectomy. <i>Journal of Clinical Oncology</i> , 2013, 31, 167-167.	1.6	0
62	Prediction of patient-reported bowel quality of life (QOL) after dose-escalated radiation therapy (RT) for prostate cancer by rectal dosimetry. <i>Journal of Clinical Oncology</i> , 2013, 31, 84-84.	1.6	0
63	Gleason pattern 5 as a pathologic predictor of recurrence, development of metastasis, and prostate cancer-specific death for patients receiving salvage radiation therapy following radical prostatectomy. <i>Journal of Clinical Oncology</i> , 2013, 31, 151-151.	1.6	0
64	Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancer. <i>Cancer</i> , 2012, 118, 2059-2068.	4.1	19
65	Nomogram predicting treatment-related bowel dysfunction for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), and brachytherapy (PI). <i>Journal of Clinical Oncology</i> , 2012, 30, 55-55.	1.6	0
66	Prospective Analysis of Parametric Response Map-Derived MRI Biomarkers: Identification of Early and Distinct Glioma Response Patterns Not Predicted by Standard Radiographic Assessment. <i>Clinical Cancer Research</i> , 2011, 17, 4751-4760.	7.0	84
67	Adjuvant radiotherapy after radical prostatectomy: Evidence and analysis. <i>Cancer Treatment Reviews</i> , 2011, 37, 89-96.	7.7	14
68	The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: Evaluation and optimization in patients at higher risk of relapse. <i>Radiotherapy and Oncology</i> , 2011, 101, 513-520.	0.6	13
69	Older Age Predicts Decreased Metastasis and Prostate Cancer-Specific Death for Men Treated With Radiation Therapy: Meta-Analysis of Radiation Therapy Oncology Group Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1293-1301.	0.8	42
70	Gleason Pattern 5 Is the Greatest Risk Factor for Clinical Failure and Death From Prostate Cancer After Dose-Escalated Radiation Therapy and Hormonal Ablation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e351-e360.	0.8	68
71	Prediction of Erectile Function Following Treatment for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1205.	7.4	253
72	Pharmacokinetic Analysis and Phase 1 Study of MRX-1024 in Patients Treated with Radiation Therapy with or without Cisplatin for Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2666-2676.	7.0	26

#	ARTICLE	IF	CITATIONS
73	Parametric Response Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2293-2299.	1.6	202
74	Inhibition of mTOR Radiosensitizes Soft Tissue Sarcoma and Tumor Vasculature. <i>Clinical Cancer Research</i> , 2009, 15, 589-596.	7.0	42
75	The parametric response map is an imaging biomarker for early cancer treatment outcome. <i>Nature Medicine</i> , 2009, 15, 572-576.	30.7	187
76	A Feasibility Study of Parametric Response Map Analysis of Diffusion-Weighted Magnetic Resonance Imaging Scans of Head and Neck Cancer Patients for Providing Early Detection of Therapeutic Efficacy. <i>Translational Oncology</i> , 2009, 2, 184-190.	3.7	146
77	Diffusion Magnetic Resonance Imaging: An Imaging Treatment Response Biomarker to Chemoradiotherapy in a Mouse Model of Squamous Cell Cancer of the Head and Neck. <i>Translational Oncology</i> , 2008, 1, 187-194.	3.7	42
78	Gemcitabine-Mediated Radiosensitization of Human Soft Tissue Sarcoma. <i>Translational Oncology</i> , 2008, 1, 50-56.	3.7	17
79	Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 3387-3394.	1.6	264
80	Revoking the Privilege: Targeting HER2 in the Central Nervous System: Fig. 1.. <i>Molecular Pharmacology</i> , 2008, 73, 271-273.	2.3	11
81	Evaluation of $\alpha$ -Methionine as a Novel Oral Radiation Protector for Prevention of Mucositis. <i>Clinical Cancer Research</i> , 2008, 14, 2161-2170.	7.0	51
82	Noninvasive Molecular Imaging Sheds Light on the Synergy between 5-Fluorouracil and TRAIL/Apo2L for Cancer Therapy. <i>Clinical Cancer Research</i> , 2007, 13, 1839-1846.	7.0	39
83	Diffusion Magnetic Resonance Imaging: A Biomarker for Treatment Response in Oncology. <i>Journal of Clinical Oncology</i> , 2007, 25, 4104-4109.	1.6	306
84	Imaging of Proteolytic Activity Using a Conditional Cell Surface Receptor. <i>Molecular Imaging</i> , 2006, 5, 7290.2006.00014.	1.4	7
85	Real-time Evaluation of p53 Oscillatory Behavior In vivo Using Bioluminescent Imaging. <i>Cancer Research</i> , 2006, 66, 7482-7489.	0.9	89
86	The Extent and Severity of Vascular Leakage as Evidence of Tumor Aggressiveness in High-Grade Gliomas. <i>Cancer Research</i> , 2006, 66, 8912-8917.	0.9	66
87	Inhibition of Vascular Endothelial Growth Factor (VEGF)-A Causes a Paradoxical Increase in Tumor Blood Flow and Up-Regulation of VEGF-D. <i>Clinical Cancer Research</i> , 2006, 12, 1525-1532.	7.0	44
88	Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor – a pharmacokinetic study. <i>Journal of Neuro-Oncology</i> , 2005, 73, 225-238.	2.9	20
89	Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 16759-16764.	7.1	270
90	Therapeutic Efficacy of DTI-015 using Diffusion Magnetic Resonance Imaging as an Early Surrogate Marker. <i>Clinical Cancer Research</i> , 2004, 10, 7852-7859.	7.0	75

#	ARTICLE	IF	CITATIONS
91	The use of <sup>19</sup> F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. <i>Molecular Therapy</i> , 2004, 10, 916-928.	8.2	78
92	Extracellular expression of cytosine deaminase results in increased 5-FU production for enhanced enzyme/prodrug therapy. <i>Anticancer Research</i> , 2004, 24, 1393-9.	1.1	6
93	Noninvasive real-time imaging of apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 16551-16555.	7.1	259
94	Toward an Enzyme/Prodrug Strategy for Cancer Gene Therapy: Endogenous Activation of Carboxypeptidase A Mutants by the PACE/Furin Family of Propeptidases. <i>Human Gene Therapy</i> , 1999, 10, 235-248.	2.7	24
95	Enzyme/Prodrug Therapy for Head and Neck Cancer Using a Catalytically Superior Cytosine Deaminase. <i>Human Gene Therapy</i> , 1999, 10, 1993-2003.	2.7	64